8-K filing — Ultragenyx Pharmaceutical Inc. (RARE)
Filed: 2026-10-14 AccNo: 0001193125-26-421079 Size: 149 KB Item 1.01: Entry into a Material Definitive Agreement
Stocks · News reference
Ultragenyx Announces $203M Deal To Sell Priority Review Voucher To Unnamed Buyer
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ultragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review Voucher
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV
Ultragenyx Gene Therapy For MPS IIIA Clears EMA Validation, Holds PRIME And Orphan Designations, Will Fall Under EU Joint Clinical Assessment